The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2020 | ALTA-1L: brigatinib vs crizotinib
Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, following the first presentation of the study, Dr Newsome-Davis discusses the discusses the ALTA-1L study (NCT02737501) investigating brigatinib versus crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.
